These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31631389)

  • 21. A case of malignant atrophic papulosis with cranial nerve and peripheral nerve impairment.
    Liu F; Liu H; Zhang M; Yan W; Sang H
    An Bras Dermatol; 2015; 90(3 Suppl 1):19-21. PubMed ID: 26312664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case for diagnosis.
    Lima Lde A; Haddad Nde C; Lima RB; D'Acri AM; Martins CJ
    An Bras Dermatol; 2014; 89(3):521-2. PubMed ID: 24937836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Degos disease with an intestinal perforation: a case report.
    Zhu M; Jiang Z; Jiang R; Chong X; Sun J
    Int J Dermatol; 2014 May; 53(5):631-4. PubMed ID: 24527998
    [No Abstract]   [Full Text] [Related]  

  • 24. Malignant atrophic papulosis.
    Scheinfeld N
    Clin Exp Dermatol; 2007 Sep; 32(5):483-7. PubMed ID: 17692056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature.
    Haskin O; Falush Y; Davidovits M
    Pediatr Nephrol; 2019 Dec; 34(12):2601-2604. PubMed ID: 31520126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case of Degos disease with pleuropericardial fibrosis, jejunal perforation, hemiparesis, and widespread cutaneous lesions.
    Shahshahani MM; Hashemi P; Nemati R; Nikoo A; Mazoochy H; Rashidi A
    Int J Dermatol; 2008 May; 47(5):493-5. PubMed ID: 18412869
    [No Abstract]   [Full Text] [Related]  

  • 27. Eculizumab and renal transplantation in a patient with CAPS.
    Lonze BE; Singer AL; Montgomery RA
    N Engl J Med; 2010 May; 362(18):1744-5. PubMed ID: 20445191
    [No Abstract]   [Full Text] [Related]  

  • 28. [Complement-Mediated Mechanism and Complement Inhibitors in Guillain-Barré Syndrome].
    Kuwahara M; Kusunoki S
    Brain Nerve; 2019 Jun; 71(6):581-587. PubMed ID: 31171755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eculizumab in post-transplant C3 glomerulonephritis caused by a C3 mutation
.
    Kim JS; Foster KW; Westphal SG
    Clin Nephrol; 2020 Jan; 93(1):51-56. PubMed ID: 31661064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Malignant atrophic papulosis: a case report with severe visual and neurological impairment.
    Gutiérrez-Pascual M; Hernández-Martín A; Colmenero I; García-Peñas JJ; López-Pino MA; Torrelo A
    Pediatr Dermatol; 2011; 28(3):302-5. PubMed ID: 21133995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation.
    Carr R; Cataland SR
    Ann Hematol; 2013 Jun; 92(6):845-6. PubMed ID: 23154867
    [No Abstract]   [Full Text] [Related]  

  • 32. Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan).
    Schols S; Nunn MA; Mackie I; Weston-Davies W; Nishimura JI; Kanakura Y; Blijlevens N; Muus P; Langemeijer S
    Br J Haematol; 2020 Jan; 188(2):334-337. PubMed ID: 31840801
    [No Abstract]   [Full Text] [Related]  

  • 33. Eculizumab therapy.
    Cataland SR
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):438-9. PubMed ID: 24534107
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical challenges and images in GI. Image 2: Malignant atrophic papulosis (Degos' disease) with systemic manifestations.
    Yamaguchi N; Isomoto H; Nakayama T
    Gastroenterology; 2008 Nov; 135(5):1464, 1807. PubMed ID: 18851969
    [No Abstract]   [Full Text] [Related]  

  • 35. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
    Mallett A; Hughes P; Szer J; Tuckfield A; Van Eps C; Cambell SB; Hawley C; Burke J; Kausman J; Hewitt I; Parnham A; Ford S; Isbel N
    Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recurrent allograft C3 glomerulonephritis and unsuccessful eculizumab treatment.
    Kaartinen K; Martola L; Räisänen-Sokolowski A; Meri S
    Clin Immunol; 2018 Feb; 187():104-106. PubMed ID: 29097196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies.
    Olson SR; Lu E; Sulpizio E; Shatzel JJ; Rueda JF; DeLoughery TG
    Am J Nephrol; 2018; 48(2):96-107. PubMed ID: 30110670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prominent Degos-like skin lesions in a patient with chronic cutaneous lupus erythematosus.
    Mutizwa MM; Tang MB; Ng SK
    Dermatol Online J; 2010 Jul; 16(7):5. PubMed ID: 20673533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Degos' syndrome complicated by bowel perforation: focus on radiological findings.
    Yeung JT; Ma JK; Yung AW
    Hong Kong Med J; 2013 Apr; 19(2):174-7. PubMed ID: 23535679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
    Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.